These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
301 related articles for article (PubMed ID: 33292135)
1. Docking Paradigm in Drug Design. Sulimov VB; Kutov DC; Taschilova AS; Ilin IS; Tyrtyshnikov EE; Sulimov AV Curr Top Med Chem; 2021; 21(6):507-546. PubMed ID: 33292135 [TBL] [Abstract][Full Text] [Related]
2. An Updated Review on SARS-CoV-2 Main Proteinase (M Sabbah DA; Hajjo R; Bardaweel SK; Zhong HA Curr Top Med Chem; 2021; 21(6):442-460. PubMed ID: 33292134 [TBL] [Abstract][Full Text] [Related]
3. Proposal of novel natural inhibitors of severe acute respiratory syndrome coronavirus 2 main protease: Molecular docking and ab initio fragment molecular orbital calculations. Shaji D; Yamamoto S; Saito R; Suzuki R; Nakamura S; Kurita N Biophys Chem; 2021 Aug; 275():106608. PubMed ID: 33962341 [TBL] [Abstract][Full Text] [Related]
4. Active Learning and the Potential of Neural Networks Accelerate Molecular Screening for the Design of a New Molecule Effective against SARS-CoV-2. Yassine R; Makrem M; Farhat F Biomed Res Int; 2021; 2021():6696012. PubMed ID: 34124259 [TBL] [Abstract][Full Text] [Related]
5. In silico Study to Evaluate the Antiviral Activity of Novel Structures against 3C-like Protease of Novel Coronavirus (COVID-19) and SARS-CoV. Chunduru K; Sankhe R; Begum F; Sodum N; Kumar N; Kishore A; Shenoy RR; Rao CM; Saravu K Med Chem; 2021; 17(4):380-395. PubMed ID: 32720605 [TBL] [Abstract][Full Text] [Related]
6. A computational evaluation of targeted oxidation strategy (TOS) for potential inhibition of SARS-CoV-2 by disulfiram and analogues. Xu L; Tong J; Wu Y; Zhao S; Lin BL Biophys Chem; 2021 Sep; 276():106610. PubMed ID: 34089978 [TBL] [Abstract][Full Text] [Related]
7. Targeting SARS-CoV-2 Main Protease: A Computational Drug Repurposing Study. Baby K; Maity S; Mehta CH; Suresh A; Nayak UY; Nayak Y Arch Med Res; 2021 Jan; 52(1):38-47. PubMed ID: 32962867 [TBL] [Abstract][Full Text] [Related]
8. Combining Different Docking Engines and Consensus Strategies to Design and Validate Optimized Virtual Screening Protocols for the SARS-CoV-2 3CL Protease. Manelfi C; Gossen J; Gervasoni S; Talarico C; Albani S; Philipp BJ; Musiani F; Vistoli G; Rossetti G; Beccari AR; Pedretti A Molecules; 2021 Feb; 26(4):. PubMed ID: 33557115 [TBL] [Abstract][Full Text] [Related]
9. Computational Insights on the Potential of Some NSAIDs for Treating COVID-19: Priority Set and Lead Optimization. Abo Elmaaty A; Hamed MIA; Ismail MI; B Elkaeed E; S Abulkhair H; Khattab M; Al-Karmalawy AA Molecules; 2021 Jun; 26(12):. PubMed ID: 34205704 [TBL] [Abstract][Full Text] [Related]
10. Drugs Repurposing Using QSAR, Docking and Molecular Dynamics for Possible Inhibitors of the SARS-CoV-2 M Tejera E; Munteanu CR; López-Cortés A; Cabrera-Andrade A; Pérez-Castillo Y Molecules; 2020 Nov; 25(21):. PubMed ID: 33172092 [TBL] [Abstract][Full Text] [Related]
11. Systematic Search for SARS-CoV-2 Main Protease Inhibitors for Drug Repurposing: Ethacrynic Acid as a Potential Drug. Isgrò C; Sardanelli AM; Palese LL Viruses; 2021 Jan; 13(1):. PubMed ID: 33451132 [TBL] [Abstract][Full Text] [Related]
12. Conserved interactions required for inhibition of the main protease of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Shitrit A; Zaidman D; Kalid O; Bloch I; Doron D; Yarnizky T; Buch I; Segev I; Ben-Zeev E; Segev E; Kobiler O Sci Rep; 2020 Nov; 10(1):20808. PubMed ID: 33257760 [TBL] [Abstract][Full Text] [Related]
15. Bung N; Krishnan SR; Bulusu G; Roy A Future Med Chem; 2021 Mar; 13(6):575-585. PubMed ID: 33590764 [No Abstract] [Full Text] [Related]
16. Computational Selectivity Assessment of Protease Inhibitors against SARS-CoV-2. Fischer A; Sellner M; Mitusińska K; Bzówka M; Lill MA; Góra A; Smieško M Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669738 [TBL] [Abstract][Full Text] [Related]
17. Computational Screening Using a Combination of Ligand-Based Machine Learning and Molecular Docking Methods for the Repurposing of Antivirals Targeting the SARS-CoV-2 Main Protease. Yuda GPWC; Hanif N; Hermawan A Daru; 2024 Jun; 32(1):47-65. PubMed ID: 37907683 [TBL] [Abstract][Full Text] [Related]
18. Molecular docking, binding mode analysis, molecular dynamics, and prediction of ADMET/toxicity properties of selective potential antiviral agents against SARS-CoV-2 main protease: an effort toward drug repurposing to combat COVID-19. Rai H; Barik A; Singh YP; Suresh A; Singh L; Singh G; Nayak UY; Dubey VK; Modi G Mol Divers; 2021 Aug; 25(3):1905-1927. PubMed ID: 33582935 [TBL] [Abstract][Full Text] [Related]
19. Structure-based screening of novel lichen compounds against SARS Coronavirus main protease (Mpro) as potentials inhibitors of COVID-19. Joshi T; Sharma P; Joshi T; Pundir H; Mathpal S; Chandra S Mol Divers; 2021 Aug; 25(3):1665-1677. PubMed ID: 32602074 [TBL] [Abstract][Full Text] [Related]
20. Identification of terpenoids as potential inhibitors of SARS-CoV-2 (main protease) and spike (RBD) via computer-aided drug design. Hadni H; Fitri A; Touimi Benjelloun A; Benzakour M; Mcharfi M; Benbrahim M J Biomol Struct Dyn; 2024 Sep; 42(15):8145-8158. PubMed ID: 37548619 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]